Fremanezumab

Limits on what this shows

• Why no grade: Dual condition met across two independent research passes. No Tier A/B/C evidence of fremanezumab- or class-level mitochondrial effects was found, and no circulating claim exists to rebut. Three adjacent sources were found, across both passes, and explicitly do not qualify: a 2-patient case report (Silvestro et al. 2023, galcanezumab) and, identified this repair pass via a PubMed search-listing query ("CGRP monoclonal antibody mitochondrial"), Kaltseis et al. 2022 (single case report, monoclonal CGRP-antibody treatment in a migraine patient with a pre-existing mitochondrial SSBP1 mutation) and Primiano et al. 2022 (single case report and literature review, erenumab efficacy in a patient with pre-existing mitochondrial disease). All three describe drug tolerability or efficacy in patients who already had mitochondrial disease before treatment, not a drug-induced mitochondrial-burden mechanism; none was opened beyond the PubMed search-listing title/abstract view and none was cited for any specific claim.

Channels tried

Original pass: WebSearch (completed before the session's shared search budget was exhausted); WebFetch against ScienceDirect, PMC, MDPI, Wiley/Headache, Frontiers, Wikipedia, and the FDA label for "mitochondria"/"mitochondrial." This repair pass additionally ran: a WebFetch of the PubMed search-listing page for "CGRP monoclonal antibody mitochondrial" (succeeded; see the three titles above, none qualifying); a full-text WebFetch search of the current AJOVY and AIMOVIG (erenumab) FDA labels specifically for "mitochondria," "mitochondrial," and "ATP" (zero matches in either label); a WebFetch of a ScienceDirect topic page for migraine/mitochondrial dysfunction (404, no such page); a WebFetch of the Wikipedia Migraine article (mentions CoQ10/riboflavin as general prophylactic supplements but attributes no mitochondrial mechanism and cites no source for the claim, so not usable as evidence). Repeated WebFetch attempts this pass against the Crossref API, OpenAlex works-search endpoint, and Europe PMC REST API for mitochondrial-function terms were rejected with HTTP 429 (Crossref, at the session's shared research-API proxy, which then instructed no further retries of that host this session; OpenAlex, directly from the target API). A second, broader PubMed query was also rejected (HTTP 429 at the proxy). WebSearch could not be used this pass: the tool reported the session's 200-call budget already exhausted.

Disposition

Likely a genuine literature gap rather than a pure tooling artifact: a subcutaneous biologic has no a priori classical mitochondrial-toxicity mechanism, and the one search channel that did return usable results (PubMed search-listing) surfaced only tolerability case reports in patients with pre-existing mitochondrial disease, consistent across both research passes. A residual, narrower tooling limitation remains disclosed: Crossref, OpenAlex, and Europe PMC could not be queried directly for this exact term in either pass and should be retried specifically in a future revision.

Limits on what this shows

• Key negative/null findings: 2 of the 3 measured redox markers (FRAP, -SH) in the same study did not reach statistical significance; this is not yet a robust, multi-marker finding.
• At-risk subgroups: None identified; no subgroup data by individual drug.
• Counter-evidence on record: The cohort test is only nominally passed for fremanezumab (2 of 42 patients, not separately analyzed), so under Hard Rule 6 this can only be treated as class-level, drug-cohort-inclusive evidence, not fremanezumab-specific confirmation.

Regulatory status

Not addressed in the AJOVY FDA label; no oxidative-stress marker monitoring is required or recommended.

Population evidence

De Luca et al. 2021, J Clin Med, prospective observational study at a tertiary headache center; n=42 at baseline, 22 completed 6-month follow-up. Drug mix: erenumab n=23, galcanezumab n=17, fremanezumab n=2; no drug-stratified subgroup analysis was reported. Advanced Oxidation Protein Products (AOPP) fell from median 291.4 to 236.2 nmol/mL chloramine-equivalents (p=0.004). Ferric-Reducing Antioxidant Power (FRAP) and free thiol (-SH) groups showed no significant change (-SH trended upward only).

Mechanism

Named and biologically coherent in the reverse direction: sustained CGRP receptor stimulation is described as activating NADPH-oxidase-dependent superoxide generation that reacts with nitric oxide to form peroxynitrite (Ramírez-Expósito et al. 2026, narrative review of endogenous CGRP biology). Removing the CGRP ligand, as fremanezumab does, removes this pro-oxidant drive rather than adding one; this is a class-level mechanistic inference, not a fremanezumab-specific demonstration.

Counter-evidence held on record

Framing caution This is not a nutrient-deficiency signal and supports no supplementation claim in either direction. It is listed because a consumer-facing "CGRP drugs cause oxidative damage" claim could plausibly circulate, and the one drug-cohort-inclusive study available points the opposite way.

Limits on what this shows

• Key negative/null findings: The pooled phase 3 safety analysis (Diener et al. 2022, n=2,842) reports adverse-event rates only, with no laboratory or hematologic panel data, so it neither supports nor refutes an iron signal for fremanezumab specifically.
• At-risk subgroups: Pre-existing iron deficiency is common in migraine patients broadly, particularly menstruating women, independent of which prophylactic therapy, if any, they receive.
• Counter-evidence on record: Confounding by indication is the default explanation here (Hard Rule 6): any iron deficiency observed in a fremanezumab-treated migraine population is, on current evidence, attributable to the underlying migraine population's baseline iron status, not to the drug. A sibling CGRP-class dossier in this batch (galcanezumab) documents the same population-level context flag independently, from the same source.

Regulatory status

Not addressed anywhere in the AJOVY label; iron is not a named interaction or monitoring parameter, and a full-text search of the current label for "iron," "ferritin," and "hepcidin" (run this repair pass) returned no matches.

Population evidence

Nwosu M. Iron Deficiency Anemia and Migraine: A Literature Review of the Prevalence, Pathophysiology, and Therapeutic Potential. Cureus. 2024 Sep 18;16(9):e69652. DOI 10.7759/cureus.69652. Narrative literature review of the disease-level association between iron deficiency anemia and migraine, opened and verified directly for this repair pass; reports a higher prevalence of iron deficiency anemia among migraine sufferers, particularly women, and a significant inverse relationship between serum ferritin and migraine severity in the studies it reviews. No CGRP monoclonal antibody, fremanezumab, or any migraine-prophylaxis drug is in the reviewed cohort; this is disease-epidemiology literature, not drug-safety literature, and does not pass the Step 4 cohort test above Tier C/D for fremanezumab specifically.

Mechanism

None specific to fremanezumab. The proposed disease-level mechanism concerns iron's role in neurovascular and neurotransmitter function and is unrelated to CGRP-antibody pharmacology; fremanezumab has no absorption-interference, hepatic-induction, or renal-wasting mechanism that would plausibly alter iron status (Step 1 PK prescreen).

Counter-evidence held on record

Framing caution This is a population-context flag, not a fremanezumab-specific deficiency claim. Do not attribute a patient's iron deficiency to fremanezumab therapy; evaluate it the same way it would be evaluated in any migraine patient, drug-treated or not. No iron dose is recommended on the basis of this entry.

Limits on what this shows

• Why no grade: Dual condition met across two independent research passes. No Tier A/B/C evidence and no circulating claim were found for copper specifically.

Channels tried

Original pass: WebSearch queries on CGRP and trace-mineral homeostasis (returned general copper/iron physiology reviews unrelated to CGRP or this drug); WebFetch review of the FDA label (no mention of copper). This repair pass additionally ran: a full-text WebFetch search of the current AJOVY label specifically for "copper," "ceruloplasmin," "iron," "ferritin," "hepcidin," "hemoglobin," "hematocrit," "anemia," "mitochondria," and "ATP" (zero matches for any term); the same full-text search against the AIMOVIG (erenumab) label as a class-level check (zero matches for any term); WebFetch attempts against the Crossref API, OpenAlex works-search endpoint, and Europe PMC REST API for CGRP-antibody-plus-copper queries, all rejected with HTTP 429 (Crossref at the session's shared research-API proxy, which instructed no further retries of that host this session; OpenAlex directly from the target API). A direct PubMed search-listing query specifically for copper could not be attempted after an earlier HTTP 429 response from that same host this pass carried an explicit instruction not to retry it further this session. WebSearch could not be used this pass: the tool reported the session's 200-call budget already exhausted.

Disposition

No plausible classical mechanism applies (not orally absorbed, no chelation, no hepatic enzyme induction, no ceruloplasmin or copper-transporter interaction described anywhere in either this drug's or erenumab's label), consistent with a genuine absence rather than concealment. The PubMed, Crossref, OpenAlex, and Europe PMC channels remain only partially queried for this exact term, due to the access block confirmed again this pass, and should be re-checked directly before this gap is treated as fully settled.

Limits on what this shows

• Key negative/null findings: A dedicated PubMed search for ("CGRP" AND "monoclonal" AND "antibody" AND "microbiome") returned zero results (accessed this review, before the host was blocked); no drug-specific or class-level microbiome-composition study exists in either direction.
• At-risk subgroups: Patients with pre-existing constipation or slow-transit disorders, per label caution.
• Counter-evidence on record: None available; this is an absence of data on the microbiome step specifically, not evidence against an effect.

Regulatory status

AJOVY USPI §5.2 (added post-approval): "Constipation with serious complications has been reported following the use of monoclonal antibody CGRP antagonists, including AJOVY, in the postmarketing setting," including hospitalization and surgery in some cases.

Population evidence

SAFE-CGRP (Sanabria-Gago et al. 2025, Front Neurol ), multicenter retrospective cohort of 353 migraine patients with comorbidities drawn from 2,042 reviewed; fremanezumab was 43% of the cohort. Constipation was reported in 18% of patients overall, a real, drug-specific, Tier A clinical finding for constipation itself, not for microbiome composition.

Mechanism

Mechanism A (altered transit time): CGRP antagonism reduces colonic motor and prosecretory activity, per the FDA label's own causal language. A paper specifically modeling this mechanism ("Constipation Caused by Anti-CGRP Migraine Therapeutics...") was identified by title but could not be opened (bot-verification gate); it is not cited for any specific claim here (see Sources). The extension from altered transit to microbiome composition is plausible but unconfirmed.

Counter-evidence held on record

Framing caution The constipation itself is the drug's documented on-target pharmacodynamic effect, not a nutrient deficiency, and is not separately graded here. Only the unstudied, theoretical microbiome-composition extension is captured in this entry; no probiotic, fiber, or other supplement claim is supported by direct evidence.

Limits on what this shows

• Key negative/null findings: The pooled phase 3 safety analysis (Diener et al. 2022, n=2,842 across HALO-EM, HALO-CM, FOCUS) reported no laboratory or metabolic-panel data and only a minimal, nonspecific fatigue signal (2% fremanezumab vs 1% placebo); no human energy-metabolism signal either way.
• At-risk subgroups: None identified.
• Counter-evidence on record: No human clinical confirmation exists in either direction; the rodent mechanism may not translate to this antibody or to humans.

Regulatory status

Not addressed in the AJOVY label; not a recognized adverse-effect category.

Population evidence

None in humans and none in fremanezumab-treated patients specifically. The only supporting data are rodent and mechanistic.

Mechanism

Ramírez-Expósito et al. 2026 ( Int J Mol Sci, narrative review): "endogenous CGRP contributes to high-fat-diet-induced weight gain by inhibiting sympathetic activity and reducing energy expenditure; its blockade improves insulin sensitivity and reduces adiposity in murine obesity models." This is class-level and mechanistic: it concerns CGRP blockade broadly (genetic or pharmacologic in mice), not fremanezumab by name, and the cohort is mice, not this drug's clinical trial population, so it is Tier C/B for this specific drug under the cohort test.

Counter-evidence held on record

Framing caution Reverse-direction and purely theoretical; this is explicitly not a basis for any ATP-support or energy supplement recommendation.

Limits on what this shows

• Key negative/null findings: No anemia, hemoglobin, or hematocrit abnormality is reported anywhere in the AJOVY label or in the pooled phase 3 safety dataset reviewed; a full-text search of the current label for "hemoglobin," "hematocrit," and "anemia" (run this repair pass) returned zero matches. A dedicated WebSearch for a CGRP-monoclonal-antibody hemoglobin/hematocrit signal, the specific query flagged as not run in the original pass, was attempted this pass but could not be issued: this session's WebSearch budget was already exhausted (200 of 200 calls) when it was attempted. A direct WebFetch follow-up of the same terms against PubMed's search-listing page was rejected (HTTP 429, rate-limited) by the session's shared research-API proxy before results could be returned, with an explicit instruction not to retry that host further this session.
• At-risk subgroups: Label notes closer monitoring for patients with pre-existing hypertension risk factors or a prior Raynaud's history.
• Counter-evidence on record: Sibling CGRP monoclonal antibodies in this batch (erenumab, eptinezumab) document the identical vasomotor pattern from their own labels and grade it the same way, confirming this is a class-wide, on-target pharmacodynamic effect rather than a fremanezumab-specific idiosyncrasy or a true oxygen-delivery deficiency.

Regulatory status

AJOVY USPI §5.3 (new-onset or worsening hypertension, onset often within the first week after dosing; monitor blood pressure and manage or discontinue as needed) and §5.4 (development, recurrence, or worsening of Raynaud's phenomenon; median postmarketing symptom onset 71 days after dosing; discontinue if symptoms develop).

Population evidence

Postmarketing pharmacovigilance reports specific to AJOVY, as compiled in the current FDA label; the label gives no numeric incidence rate for either event. No hemoglobin, hematocrit, or anemia signal accompanies either warning, and the pooled phase 3 safety analysis (Diener et al. 2022, n=2,842) reports no laboratory or blood-pressure panel data at all.

Mechanism

Named and drug-specific: CGRP is an endogenous vasodilator; antibody neutralization of circulating CGRP removes this vasodilatory tone, which can manifest as hypertension or peripheral vasospasm (Raynaud's) in susceptible patients. This is the same CGRP blockade that produces fremanezumab's intended migraine-preventive effect, not a separate nutrient-handling pathway, and is excluded from a deficiency-style grade under Hard Rule 2 for exactly that reason.

Counter-evidence held on record

Why this is not graded as a deficiency, Hard Rule 2 The vascular signal here is hemodynamic (vessel tone), not a blood oxygen-carrying-capacity or nutrient signal, and it is not converted into an iron, copper, or B12 claim in this dossier. Framing caution: do not read this entry as a case for iron or any oxygen-carrying-capacity supplement. New or worsening hypertension, or digit color change, numbness, or pain, should be reported to the prescriber promptly; neither is addressed by supplementation.